Canaccord Genuity Reiterates a 'Buy' on Heartware Int'l (HTWR); Huge Q1 on Top Share in OUS

Article Stock Quotes (1) Comments (0)

Canaccord Genuity reiterates a 'Buy' on Heartware Int'l (NASDAQ: HTWR) price target raised from $95 to $101.

Analyst, Jason R. Mills, said, "With HTWR crushing Q1 results, taking over the #1 LVAD share position OUS for the first time, and offering a plethora of potentially favorable upcoming catalysts (FDA approval and launch, first in man for MVAD, GLP studies for fully-implantable device), we reiterate HTWR as one of our best ideas for 2012. HTWR crushed our/consensus Q1 estimates, with OUS HVAD sales growing over 60% Y/Y, and eclipsing our estimate by ~50%. Currently in discussions with FDA on HVAD labeling and a post-approval study, HTWR is seemingly on track to hit our launch estimate of September."

"We raise our 2012 sales/loss per share (LPS) estimates to $134.4M/$(4.65) from $125.5M/$(5.06)."

For an analyst ratings summary and ratings history on Heartware Int'l click here. For more ratings news on Heartware Int'l click here.

Shares of Heartware Int'l closed at $77.14 yesterday, with a 52 week range of $53.40-$81.06.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• UPDATE: UBS Downgrades Carnival (CCL) to Neutral; Worst May Not Be Behind
• Dougherty & Co Raises PT on SodaStream (SODA) to $80
• Goldman Sachs Upgrades Abbott Labs (ABT) to Buy

Create E-mail Alert Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?